Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GSK2190915 Milled Tablet
GSK2190915 Milled · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Period 1 Cohort 1 - GSK2190915 100mg | EXPERIMENTAL | Period 1 - GSK2190915 100mg tablet. |
| Period 1 Cohort 2 - GSK2190915 100mg plus microtracer | EXPERIMENTAL | Period 1 - GSK2190915 100mg tablet plus \[14C\] radiolabelled GSK2190915 microtracer solution. |
| Period 2 GSK2190915 100mg to proximal small bowel | EXPERIMENTAL | 100mg of ground half 200mg GSK2190915 tablet administered to the proximal small bowel via Enterion capsule. |
| Period 3 GSK2190915 100 mg to distal small bowel | EXPERIMENTAL | 100mg of ground half 200mg GSK2190915 tablet administered to the distal small bowel via Enterion capsule. |
| Period 4 - GSK 100mg enteric-coated tablet | EXPERIMENTAL | 100mg enteric-coated GSK2190915 coated tablet. |
| Name | Type | Description |
|---|---|---|
| GSK2190915 100mg milled tablet | DRUG | Taken orally |
| [14C] radiolabelled GSK2190915 solution | DRUG | Microtracer solution |
| GSK2190915 100mg milled tablet administered to the proximal small bowel. | DRUG | Ground half of a 200mg tablet. Administered via Enterion capsule. |
| GSK2190915 100mg milled tablet administered to the distal small bowel. | DRUG | Ground half of a 200mg tablet. Administered via Enterion capsule. |
| GSK2190915 100mg enteric-coated tablet. | DRUG | Taken orally |
Inclusion Criteria: * Healthy females as determined by an experienced study physician, based on a medical evaluation including medical history, physical examination, neurological examination, laboratory tests and electrocardiogram (ECG). A subject with a clinical abnormality or laboratory parameter...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
GSK2190915 Milled is an investigational small molecule developed by GSK plc for asthma. It is a milled tablet formulation of GSK2190915, specifically a 100mg milled tablet, studied in a Phase 1 clinical trial. The drug has not been approved and remains in clinical development.
GSK2190915 Milled is being studied for the treatment of asthma. It is an investigational therapy and has not been approved for any indication. The only clinical trial to date enrolled healthy female volunteers to assess the drug's absorption and bioavailability.
GSK2190915 Milled is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the Phase 1 trial evaluating this milled tablet formulation for asthma.
GSK2190915 Milled is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The drug is investigational and has not received FDA approval.
GSK2190915 Milled has been evaluated in one completed Phase 1 trial, NCT01318980, titled "A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A." The trial enrolled 14 healthy female volunteers in the United Kingdom and is now completed.